Published in J Acquir Immune Defic Syndr on October 01, 2002
Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology (2004) 3.44
Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A (2005) 2.79
3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage (2006) 2.69
Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology (2004) 2.54
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol (2009) 1.57
Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev (2008) 1.52
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol (2010) 1.25
Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol (2004) 1.24
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study. AIDS Res Ther (2012) 1.15
Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci (2005) 1.12
Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci (2009) 1.08
Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb. Am J Pathol (2004) 1.05
Regional cortical thinning associated with detectable levels of HIV DNA. Cereb Cortex (2011) 1.02
HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia (2009) 1.02
Neurologic disease in captive lions (Panthera leo) with low-titer lion lentivirus infection. J Clin Microbiol (2006) 0.93
HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1. J Gene Med (2006) 0.93
Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques. Am J Pathol (2010) 0.92
HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol (2008) 0.92
Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun (2014) 0.92
Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials (2010) 0.91
The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders. AIDS Behav (2008) 0.91
Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs (2010) 0.91
Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol (2006) 0.90
Feline immunodeficiency virus neuropathogenesis: from cats to calcium. J Neuroimmune Pharmacol (2006) 0.90
Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther (2008) 0.89
HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther (2015) 0.89
4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis. J Neuroimmune Pharmacol (2009) 0.89
Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener (2014) 0.87
Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity. Mol Cell Neurosci (2011) 0.87
An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol (2008) 0.87
Neuropathology of AIDS: An Autopsy Review of 284 Cases from Brazil Comparing the Findings Pre- and Post-HAART (Highly Active Antiretroviral Therapy) and Pre- and Postmortem Correlation. AIDS Res Treat (2012) 0.86
Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia. BMC Infect Dis (2009) 0.86
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. Antimicrob Agents Chemother (2013) 0.86
Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate. J Virol (2005) 0.85
Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase. Neurotherapeutics (2010) 0.84
Second assessment of NeuroAIDS in Africa. J Neurovirol (2008) 0.84
Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders. J Neurovirol (2013) 0.84
A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia. PLoS One (2012) 0.82
A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. Neuropsychiatry (London) (2011) 0.81
Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis (2007) 0.81
Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration. Cell Death Differ (2015) 0.80
Do common mental disorders decline over time in TB/HIV co-infected and HIV patients without TB who are on antiretroviral treatment? BMC Psychiatry (2013) 0.79
Brain biopsy in AIDS patients: diagnostic yield and treatment applications. AIDS Res Ther (2014) 0.77
Gene expression patterns associated with neurological disease in human HIV infection. PLoS One (2017) 0.75
The inhibition of microRNAs by HIV-1 Tat suppresses beta catenin activity in astrocytes. Retrovirology (2016) 0.75
Clinical utility of magnetic resonance spectroscopy to enhance diagnosis of HIV-associated mild neurocognitive disorder. Neuropsychiatry (London) (2012) 0.75
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Age affects outcomes in chronic kidney disease. J Am Soc Nephrol (2007) 5.36
Association of journal quality indicators with methodological quality of clinical research articles. JAMA (2002) 5.13
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med (2008) 3.64
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS (2006) 2.72
Physician predictors of mammographic accuracy. J Natl Cancer Inst (2005) 2.72
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med (2007) 2.36
Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35
Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med (2007) 2.33
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia. Ann Emerg Med (2007) 2.18
White/black racial differences in risk of end-stage renal disease and death. Am J Med (2009) 2.16
Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust (2006) 2.14
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 2.10
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis (2006) 2.06
Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr (2008) 2.05
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 1.94
The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr (2008) 1.94
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis (2011) 1.90
Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA (2006) 1.90
The management of needlestick injuries. Dtsch Arztebl Int (2013) 1.89
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS (2002) 1.87
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Frequency of trigeminal nerve injuries following third molar removal. J Oral Maxillofac Surg (2005) 1.84
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis (2003) 1.82
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A (2013) 1.80
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis (2005) 1.76
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol (2002) 1.74
Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol (2003) 1.73
Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat Appl Genet Mol Biol (2004) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med (2005) 1.69
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation (2004) 1.68
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS (2003) 1.66
Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant (2003) 1.65
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr (2008) 1.63
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis (2007) 1.62
Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol (2010) 1.60
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol (2003) 1.57
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol (2007) 1.57
The impact of Medicaid managed care on hospitalizations for ambulatory care sensitive conditions. Health Serv Res (2005) 1.55
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 1.53
Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic. Med Care (2004) 1.51
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis (2002) 1.46
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. J Pediatr (2006) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav (2012) 1.44
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Pupil examination: validity and clinical utility of an automated pupillometer. J Neurosci Nurs (2005) 1.42
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med (2004) 1.41